Tower Research Capital LLC (Trc) Alzamend Neuro, Inc. Transaction History

Tower Research Capital LLC (Trc)

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.19 - $0.52 $5,963 - $16,320	31,385 Added 182.26%	48,605 $11,000
Q2 2023 Aug 14, 2023	SELL	$0.49 - $0.77 $5,843 - $9,183	-11,926 Reduced 40.92%	17,220 $8,000
Q1 2023 May 09, 2023	BUY	$0.37 - $0.71 $4,515 - $8,665	12,205 Added 72.04%	29,146 $12,000
Q4 2022 Feb 10, 2023	BUY	$0.53 - $222.0 $8,978 - $3.76 Million	16,941 New	16,941 $10,000
Q2 2022 Aug 15, 2022	BUY	$0.82 - $1.2 $2,473 - $3,620	3,017 Added 24.63%	15,266 $13,000
Q1 2022 May 12, 2022	BUY	$0.91 - $2.23 $11,146 - $27,315	12,249 New	12,249 $15,000
Q4 2021 Feb 14, 2022	SELL	$1.9 - $3.08 $50,427 - $81,746	-26,541 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.28 - $7.68 $55,850 - $188,129	24,496 Added 1197.85%	26,541 $82,000
Q2 2021 Aug 16, 2021	BUY	$8.12 - $13.5 $16,605 - $27,607	2,045 New	2,045 $18,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $115M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.